Harimoto Norifumi, Shimada Mitsuo, Aishima Shin-ichi, Kitagawa Dai, Itoh Shinji, Tsujita Eiji, Maehara Shin-ichiro, Taketomi Akinobu, Tanaka Shinji, Shirabe Ken, Maehara Yoshihiko
Department of Surgery, Graduate School of Medical Sciences, Kyushu University, Higashi-ku, Fukuoka, Japan.
Liver Int. 2004 Aug;24(4):316-21. doi: 10.1111/j.1478-3231.2004.0927.x.
A recent report showed that heat shock protein (HSP)-27 expression was related to histological grade and survival of patients with hepatocellular carcinoma (HCC).
The aim of this study was to examine the effect of expression of HSP-27 on clinicopathological variables in Japanese patients with HCC.
An immunohistochemical study for HSP-27 was performed on 60 HCC cases using a monoclonal anti-HSP-27 antibody. We divided 60 patients into two groups, patients with a low expression of HSP-27 (n = 34) and those with a high expression of HSP-27 (n = 26). Forty patients tested positive for the hepatitis C virus (HCV) antibody and 20 tested positive for the hepatitis B surface antigen.
There appeared to be no relationship between HSP expression and clinicopathologic factors and no differences were observed between the high expression group and the low expression group. In the hepatitis B virus (HBV) group (n = 20), HSP-27 expression correlated significantly with prognosis, disease-free survival (DFS) and overall survival. High expression was significantly associated with poor prognosis in the HBV group. In contrast, patients with a high expression tended to have a good prognosis in the HCV group (n = 40): DFS and overall survival.
This study showed the possibility that HSP-27 plays different roles in HBV- and HCV-associated HCCs.
最近的一份报告显示,热休克蛋白(HSP)-27的表达与肝细胞癌(HCC)患者的组织学分级和生存率相关。
本研究的目的是检测HSP-27表达对日本HCC患者临床病理变量的影响。
使用单克隆抗HSP-27抗体对60例HCC病例进行HSP-27的免疫组织化学研究。我们将60例患者分为两组,HSP-27低表达组(n = 34)和HSP-27高表达组(n = 26)。40例患者丙型肝炎病毒(HCV)抗体检测呈阳性,20例患者乙型肝炎表面抗原检测呈阳性。
HSP表达与临床病理因素之间似乎没有关系,高表达组和低表达组之间未观察到差异。在乙型肝炎病毒(HBV)组(n = 20)中,HSP-27表达与预后、无病生存期(DFS)和总生存期显著相关。在HBV组中,高表达与预后不良显著相关。相比之下,在HCV组(n = 40)中,高表达患者倾向于有较好的预后:DFS和总生存期。
本研究表明HSP-27在HBV和HCV相关的HCC中可能发挥不同作用。